IMS Health RWES at ISPOR Singapore

ISPOR 7th Asia-Pacific Conference3-6 September 2016, Singapore

Join us for the IMS Health Symposium“How real-world evidence (RWE) can enablepharma to partner in healthcare delivery”Meet the largest expert community in RWE Discover the findings from our latest research

IMS Health Real-World Evidence Solutionsat ISPOR, Singapore, September 2016

Live Sessionswith IMS Health

2

IMS Health invites you to join us for a compelling program of activities at the ISPOR7th Asia-Pacific Conference. With demand for real-world evidence (RWE) growingfast across the region, we are excited to share our perspective on the innovativeapproaches that will be key to strengthening its creation and value going forward.

Reflecting our commitment to bringing insights from real-world data (RWD) to improve decisionmaking and patient outcomes, our research contributions at ISPOR demonstrate its power andpotential to inform healthcare issues in countries throughout Asia Pacific.

An overview of our symposium, workshops, posters and panel participation at the event can be foundin this brochure. Members of our global, regional and local RWE Solutions team will be on hand rightthrough, at the IMS Health booth (32–33).

We look forward to seeing you in Singapore!

Welcome to IMS Health at ISPOR, Singapore

Pre-Conference Short Courses • Patient-reported outcomes measures (PROMs):Cross-cultural development and validation3 September, 13:00–17:00

• Health care systems in Asia4 September, 08:00–12:00

Educational Symposium • How real-world evidence (RWE) can enablepharma to partner in healthcare delivery5 September, 13:15–14:15

Workshops• Value proposition development: Communicatingvalue in the patients’ language4 September, 17:00–18:00

• Introducing a novel concept to observationalresearch in the Asia-Pacific region: Enriched real-world data studies6 September, 16:00–17:00

ISPOR Forum • Big data in Asia-Pacific – a valuable resourcefor better healthcare decisions: Experiencesand lessons learned in Australia, Japan,Singapore, South Korea and Taiwan6 September, 08:30–09:30

See pages 3–6 for further details

ISPOR 7th Asia-Pacific Conference, 3-6 September 2016, Singapore

3

IMS Health Symposium Monday, 5 September

“How real-world evidence (RWE) can enable pharma to partner in healthcare delivery”RWE is increasingly prominent on the global stage, helping pharmaceutical manufacturers, reimbursementdecision makers, HTA organizations and clinicians better understand diseases, patient treatment and outcomes.Yet it is just at an early stage in Asia Pacific and given its current state compared to the USA or Europeanmarkets, there is an increasing sense of urgency to find ways of developing useful RWE in this region.

Decision makers are seeking more evidence to support their assessments, putting greater pressure on theindustry to develop re-usable data infrastructures and novel approaches to data generation, and workmore collaboratively to help integrate disparate data while maintaining patient privacy.

This symposium will provide an overview of the need for RWE and availability of RWD in Asia Pacific todaybut focus on advances and methodologies that would help companies generate more RWE in the region.Innovative approaches include partnerships involving and aligning different healthcare stakeholders aswell as “mosaic” and enriched approaches.

Discussing these issues, our panel will include senior representatives from the pharmaceutical industryand research institutions as well as experts from IMS Health.

Agenda

Introduction: The increasing need for RWE in Asia Pacific 13:15–13:20 Bruce Crawford, MA, MPH (Chair), Senior Principal, RWE Solutions, Japan & APAC, IMS Health, Tokyo, Japan

Growing demand for evidence by payers in Asia: An industry perspective on possible ways forward to create RWE in the region 13:20–13:35 Aileen Dualan, MD, MS, Chief Scientific Officer, Asia Cluster, Novartis Asia Pacific Pharmaceuticals, Singapore

Novel partnership approaches to generate RWE across Asia Pacific 13:35–13:50 Christopher J. King, MBA, Oncology Head, APAC, IMS Health, Singapore

Innovative methodological approaches to enrich existing data assets in Asia Pacific 13:50–14:05Karen Wai, MB BCh BAO, MBA, VP, Regional Managing Director, Real-World & Late Phase Research Asia Pacific, Quintiles, Singapore

Moderated Q&A 14:05–14:15 Bruce Crawford, MA, MPH (Chair)

Proceedings from the symposium can be obtained from IMS Health. To receive a copy, please email Angelika Boucsein at [email protected]

IMS Health Real-World Evidence Solutions

4ISPOR 7th Asia-Pacific Conference, 3-6 September 2016, Singapore

Symposium PanelBruce Crawford, MA, MPH is Senior Principal, Real-World Evidence Solutions, Japan and Asia Pacific &China, at IMS Health in Tokyo. He has more than 20 years of consulting experience and expertise inprospective study design, patient-reported outcome evaluations, cost-effectiveness analyses andreimbursement, and has worked on projects throughout Asia for the last 13 years. Bruce was previouslyManaging Director Asia and Senior VP at Adelphi, prior to which he served as Operations Director at MapiValues. He has also worked in Managed Care and for a major CRO as a health economist, as well as beinginvolved in research and training with the US FDA, the Japanese PMDA, and the Thailand FDA and National Listof Essential Drugs Committee. Bruce has written and lectured on pharmacoeconomic and outcomes researchmethodologies and impacts on study validity, and held appointments as Adjunct Project Professor of HTA andPublic Policy at Tokyo University Graduate School of Public Policy and as Adjunct Instructor at Kyoto UniversitySchool Of Medicine and Public Health, Department of Pharmacoepidemiology.

Aileen Dualan, MD, MS is Chief Scientific Officer, Asia at Novartis Pharmaceuticals in Singapore, whereshe has been working since 2013. She is also President of APMS, the Association of Pharmaceutical Medicine(Singapore), a role she assumed in 2015. Dr. Dualan has 13 years of experience in the pharmaceutical industry.She has been based in Singapore since 2010, serving in various regional medical roles. Prior to this she heldpositions in medical affairs, development and pharmacovigilance in the Philippines. Dr. Dualan’s experiencebefore joining the industry was heavily focused on research and academics. A board certified pediatrician, shewas admitted as a Diplomate of the American Board of Pediatrics in 1997. She is currently a PhD candidate inEpidemiology, having further supported her endeavors in the corporate world by obtaining a Certificate ofBusiness Leadership in 2006 and more recently a Certification in Health Economics.

Christopher J. King, MBA is Oncology Head, Asia Pacific & China at IMS Health in Singapore, where heleads the direction of next-generation RWE offerings and services and is the therapeutic expert for oncology-related consulting engagements in the region. He has expertise in RWE strategic solutions, commercial productforecast modeling, market and product assessments, and product positioning/launch strategy. Prior to joiningIMS Health, Chris was Head of the European Oncology Monitor at Ipsos, responsible for product development,team leadership, staff management and client servicing for its European Oncology Monitor business. He waspreviously with the Healthcare Consulting practice at DataMonitor, working on various global strategicpharmaceutical and biotech consultancy projects covering major as well as emerging markets. Chris also hasclinical research experience, gained at the British Columbia Cancer Research Centre where he was responsiblefor database design and implementation, quality control and statistics.

Karen Wai, MB BCh BAO, MBA is VP, Regional Managing Director, Real-World & Late Phase ResearchAsia Pacific, at Quintiles in Singapore, leading a team that delivers innovative solutions in this space in theregion. A physician by training and an experienced medical and pharmaceutical healthcare expert, she hasserved as Medical and Scientific Advisor for more than 60 clinical trial protocols in oncology, neurology,cardiovascular, anti-infective and rheumatoid arthritis indications. Dr. Wai has leveraged her medical andsafety background to continue her career enhancing efficiency and quality during clinical trial planning, andbuilt relationships with multiple investigators and physicians around the globe and, in particular, the Asia-Pacific region. She is also passionate about engaging the patient throughout the product or device lifecycle.Prior to joining Quintiles, Dr. Wai worked as a physician in both the public and private healthcare sector. Shehas direct management and operational experience in European, African and Asian environments.

5

IMS Health Activities 3-5 September3

SEP

TEM

BER

4 S

EPTE

MB

ER5 S

EPTE

MB

ER

CODE TOPIC PRESENTERS TYPE

PATIENT-REPORTED OUTCOMES MEASURES (PROMS): CROSS-CULTURAL DEVELOPMENT AND VALIDATION

Crawford B, Lin Wee H Pre- Conference Short Course

HEALTH CARE SYSTEMS IN ASIA Yang B-M , Crawford B, Zhao K,Sharma J

Pre- Conference Short Course

W5 VALUE PROPOSITION DEVELOPMENT: COMMUNICATING VALUE IN THE PATIENTS’ LANGUAGE

Crawford B, Wada K, Caputo J,Leartsakulpanitch J

Workshop

PHP112 LOCAL UTILITIES FOR LOCAL STUDIES: DATA AVAILABILITY AND METHODOLOGY IN JAPAN AND KOREA

Kim HR, Chen X, Pyo J, Crawford B

Research Poster

PMH18 THE MEDICATION ADHERENCE IN SCHIZOPHRENIA MANAGEMENT BY USINGSECOND GENERATION ANTIPSYCHOTICS IN TAIWAN: A POPULATION STUDYBASED ON NHRID

Chung C, Tai TA, Chou KP Research Poster

PSS1 LONG-TERM FOLLOW-UP OF RANIBIZUMAB TREATED PATIENTS WITH MYOPICCHOROIDAL NEOVASCULARIZATION FROM THE RADIANCE CLINICAL TRIAL INFOUR EAST ASIAN COUNTRIES

Skelly A, Lara N, Pedros M,Macfadden W

Research Poster

HOW REAL-WORLD EVIDENCE (RWE) CAN ENABLE PHARMA TO PARTNER INHEALTHCARE DELIVERY

Crawford B, Dualan A, King CJ, Wai K

EducationalSymposium

PRM20 FEASIBILITY OF ELECTRONIC MEDICAL RECORDS IN AUSTRALIA, CHINA, ANDJAPAN TO SUPPORT NOVELTY (A NOVEL OBSERVATIONAL LONGITUDINAL STUDY OF PATIENTS WITH ASTHMA AND/OR COPD)

Wang X, Gerhardsson de Verdier M,Sveréus A, Hiller J, Wong D, Nasuti P, Jenner H, McKenney A

Research Poster

PRS9 COPD UNCOVERED: HEALTH CARE RESOURCE USE AND COST OF CHRONICOBSTRUCTIVE PULMONARY DISEASE IN JAPAN

Igarashi A, Fukuchi Y, Hirata K,Ichinose M, Nagai A, Nishimura M,Lara N, Murata S, Gruenberger J

Research Poster

PSY3 THE IMPACT OF MEDICAL INSURANCE COVERAGE OF IMATINIB AND MOLECULAR MONITORING FREQUENCY ON OUTCOMES IN TREATMENT OFCHRONIC MYELOID LEUKAEMIA (CML): REAL-WORLD EVIDENCE IN CHINA

Chen S, Sheng G, Zhang R, Miao M,Wu D, Xiong T, Tan SC, Liu C

Research Poster

PSY13 SOCIETAL IMPLICATIONS OF MEDICAL INSURANCE COVERAGE FOR IMATINIB AS FIRST-LINE TREATMENT OF CHRONIC MYELOID LEUKAEMIA IN CHINA: A COST EFFECTIVENESS ANALYSIS

Chen S, Dong C, Sheng G, Zhang R, Miao M, Wu D, Xiong T, Tan SC, Liu C

Research Poster


6 S

EPTE

MB

ER

6

IMS Health Activities 6 September

F3 BIG DATA IN ASIA-PACIFIC – A VALUABLE RESOURCE FOR BETTER HEALTHCAREDECISIONS: EXPERIENCES AND LESSONS LEARNED IN AUSTRALIA, JAPAN,SINGAPORE, SOUTH KOREA, AND TAIWAN

Roughead L, Crawford B, Lin Wee H, Bae SJ, Chang CJ

ISPOR Forum

W12 INTRODUCING A NOVEL CONCEPT TO OBSERVATIONAL RESEARCH IN THE ASIA-PACIFIC REGION: ENRICHED REAL-WORLD DATA STUDIES

Garcia Alvarez L, Hiller J, Yoong J,Leong Seng O

Workshop

PCN32 COST-EFFECTIVENESS ANALYSIS OF OXALIPLATIN PLUSFLUOROURACIL/LEUCOVORIN (FOLFOX4) COMPARED TO SORAFENIB FORTREATMENT OF ADVANCED HEPATOCELLULAR CARCINOMA PATIENTS IN CHINA

Qin SK, Kruger E, Tan SC, Cheng SQ, Yao XX, Liang J

ResearchPoster

PCN46 PATIENT-REPORTED OUTCOMES IN JAPANESE ONCOLOGY PRODUCTS - REVIEW OF THE PMDA LABELS

Crawford B, Kim HR ResearchPoster

PDB19 THE COST-EFFECTIVENESS OF DULAGLUTIDE VERSUS LIRAGLUTIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN TAIWAN

Lin H, Babineaux S, Lew T, Lowin J,Lovato E, Strizek AA, Rajan N

ResearchPoster

PMS4 THE COMPARISONS OF BIOLOGICS WITH METHOTREXATE FOR TREATINGRHEUMATOID ARTHRITIS PATIENTS IN TAIWAN: THE USE OF COST-UTILITYANALYSIS AND BUDGET IMPACT ANALYSIS

Li C, Chou P, Chang C, Fann CS ResearchPoster

IMS Health Real-World Evidence Solutions Bibliography

Our research expertise and therapy area knowledge arecaptured in more than 3,500 publications, spanningvirtually all therapy areas and projects completed in over50 countries worldwide.

A special IMS Health RWE Solutions Oncology Bibliography will beavailable at ISPOR. This captures our wide range of HEOR and RWEpapers and presentations published since 2010 across a variety of solidand hematological cancers globally. Pick up your copy at our booth todiscover the research topics and innovative methodologies explored byour experts and tumor-specific specialists to inform key challenges inoncology today. To see our full database online, visitwww.imsrwebibliography.com.

CODE TOPIC PRESENTERS TYPE

ISPOR 7th Asia-Pacific Conference, 3-6 September 2016, Singapore

Oncology Bibliography


Published papers and presentationsin solid and hematological cancers 2010–2016

7

IMS Health Our Distinctive Approach

IMS Health has taken a holistic approach to RWE in pursuit of the most robust andinsightful views of patient outcomes. With the breadth and depth of our capabilitieswe are uniquely positioned to generate and use RWE globally.

Applying the appropriate scientific and commercial lens and latest techniques to anonymous RWD is critical to realizing the value of RWE in healthcare decisions.


IMS HEALTHREAL-WORLD

EVIDENCESOLUTIONS

Real-World DataIdentify and access the most appropriate data sources while ensuring patient privacy

• The broadest and deepest collection of scientifically-validated, anonymous patient-level data assets complemented by custom data sourcing

Technology-Enabled AnalyticsCreate consistent data models empowering analyses and leveraging innovativetechnologies

• Extraction, analysis and visualization of RWD with IMS Health’s E360TM technology suite • Sophisticated data linkage and interpretation

Services and EngagementAnalyze RWD using scientific rigor, clear governance and advanced analytic and processing capabilities

• Market Access & HTA• Health Economics• Outcomes Research• Pharmacoepidemiology & Drug Safety • Commercial Analytics

IMS Health can uniquely support all elements of the RWE ecosystem – an environment where all the components of RWE come together for a consistent, insightful view ofwhat really happens in healthcare. An environment which,for the first time, helps all functions realize its potential.

Nurturing your real-world success

©2016 IMS Health Incorporated and its affiliates. All rights reserved. IMS HEALTH, IMS HEALTH INTELLIGENCE APPLIED and E360 are trademarks of IMS Health Incorporated.

ORB1616

IMS Health Real-World Evidence Solutionsis based in 20 countries worldwide with regional headquarters in

[email protected]

www.imshealth.com/rwe

www.linkedin.com/company/ims-health-real-world-evidence

www.twitter.com/IMSHealthRWE

Europe210 Pentonville RoadLondon N1 9JYUnited KingdomTel: +44 (0) 20 3075 4800

The Americas485 Lexington Avenue26th FloorNew York, NY 10017USATel: +1 646 596 6053

Latin AmericaInsurgentes Sur # 2375 5th FloorCol. TizapanMéxico D.F.- C.P. 01090México Tel: +52 55 5089 5205

Asia-Pacific & Japan8 Cross Street #21-01/02/03Singapore 048424SingaporeTel: +65 6412 7365

Toranomon Towers Office4-1-28 ToranomonMinato-ku Tokyo 150-0001JapanTel: +81 3 5425 9541

Our RWE experts will be running demonstrations of IMS HealthE360™ during ISPOR. This powerful suite of RWE applicationsallows researchers to answer even the most challenging questionsin a standardized, intuitive way.

Book a demonstration of IMS Health’s E360™ technology suite

Schedule your individual demonstration at the IMS Health booth (32-33) or by emailing [email protected]

IMS Health RWES at ISPOR Singapore

Healthcare

Transcript of IMS Health RWES at ISPOR Singapore